194 related articles for article (PubMed ID: 38336745)
1. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation.
Kim WK; Buckley AJ; Lee DH; Hiroto A; Nenninger CH; Olson AW; Wang J; Li Z; Vikram R; Adzavon YM; Yau TY; Bao Y; Kahn M; Geradts J; Xiao GQ; Sun Z
Nat Commun; 2024 Feb; 15(1):1231. PubMed ID: 38336745
[TBL] [Abstract][Full Text] [Related]
2. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
[TBL] [Abstract][Full Text] [Related]
5. Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes.
Kim WK; Olson AW; Mi J; Wang J; Lee DH; Le V; Hiroto A; Aldahl J; Nenninger CH; Buckley AJ; Cardiff R; You S; Sun Z
Nat Commun; 2022 Jul; 13(1):4364. PubMed ID: 35902588
[TBL] [Abstract][Full Text] [Related]
6. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
7. Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
Khurana N; Sikka SC
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027362
[TBL] [Abstract][Full Text] [Related]
8. Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.
Xu Y; Mu J; Zhou Z; Leng Y; Yu Y; Song X; Liu A; Zhu H; Li J; Wang D
Stem Cell Res Ther; 2022 Jul; 13(1):299. PubMed ID: 35841025
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
10. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
11. Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.
Yeh Y; Guo Q; Connelly Z; Cheng S; Yang S; Prieto-Dominguez N; Yu X
Adv Exp Med Biol; 2019; 1210():351-378. PubMed ID: 31900917
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer.
Chen X; Shao Y; Wei W; Zhu S; Li Y; Chen Y; Li H; Tian H; Sun G; Niu Y; Shang Z
Cell Death Dis; 2022 Nov; 13(11):927. PubMed ID: 36335093
[TBL] [Abstract][Full Text] [Related]
13. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
[TBL] [Abstract][Full Text] [Related]
15. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
16. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
[TBL] [Abstract][Full Text] [Related]
17. Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer.
Patel R; Brzezinska EA; Repiscak P; Ahmad I; Mui E; Gao M; Blomme A; Harle V; Tan EH; Malviya G; Mrowinska A; Loveridge CJ; Rushworth LK; Edwards J; Ntala C; Nixon C; Hedley A; Mackay G; Tardito S; Sansom OJ; Leung HY
Cancer Res; 2020 Feb; 80(3):576-590. PubMed ID: 31719098
[TBL] [Abstract][Full Text] [Related]
18. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
19. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]